These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 33981659)

  • 1. Study on the Experience of Public Health System Construction in China's COVID-19 Prevention.
    Zhang P
    Front Public Health; 2021; 9():610824. PubMed ID: 33981659
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of China's public health system response to COVID-19.
    Zhang P; Gao J
    J Glob Health; 2021 Jan; 11():05004. PubMed ID: 33643637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. China's Public Health Policies in Response to COVID-19: From an "Authoritarian" Perspective.
    Gao J; Zhang P
    Front Public Health; 2021; 9():756677. PubMed ID: 34976920
    [No Abstract]   [Full Text] [Related]  

  • 4. Development, Status Quo, and Challenges to China's Health Informatization During COVID-19: Evaluation and Recommendations.
    Huang M; Wang J; Nicholas S; Maitland E; Guo Z
    J Med Internet Res; 2021 Jun; 23(6):e27345. PubMed ID: 34061761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding public health in China: an empirical analysis of healthcare inputs and outputs.
    Deng F; Lv JH; Wang HL; Gao JM; Zhou ZL
    Public Health; 2017 Jan; 142():73-84. PubMed ID: 28057203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical Insurance Information Systems in China: Mixed Methods Study.
    Li Y; Lu C; Liu Y
    JMIR Med Inform; 2020 Sep; 8(9):e18780. PubMed ID: 32673209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Environmental management strategy in response to COVID-19 in China: Based on text mining of government open information.
    Kang A; Ren L; Hua C; Song H; Dong M; Fang Z; Zhu M
    Sci Total Environ; 2021 May; 769():145158. PubMed ID: 33485207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The spatial transmission of SARS-CoV-2 in China under the prevention and control measures at the early outbreak.
    Liu J; Zhou Y; Ye C; Zhang G; Zhang F; Song C
    Arch Public Health; 2021 Jan; 79(1):8. PubMed ID: 33441168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. China's Fight Against COVID-19: What We Have Done and What We Should Do Next?
    Cheng S; Zhao Y; Kaminga AC; Zhang X; Xu H
    Front Public Health; 2022; 10():548056. PubMed ID: 35844877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development and reform of public health in China from 1949 to 2019.
    Wang L; Wang Z; Ma Q; Fang G; Yang J
    Global Health; 2019 Jul; 15(1):45. PubMed ID: 31266514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "A community system": A critical foundation for the epidemic prevention and control of SARS-CoV-2.
    Zhang X; Yang S
    Int J Health Plann Manage; 2020 Sep; 35(5):1246-1249. PubMed ID: 32677114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Social Media Use for Health Communication by the CDC in Mainland China: National Survey Study 2009-2020.
    Zeng R; Li M
    J Med Internet Res; 2020 Dec; 22(12):e19470. PubMed ID: 33151892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Containment: Comparisons and Suggestions for Global Response.
    Cheng S; Zhao Y; Kaminga AC; Wang X; Zhang X; Xu H
    Inquiry; 2022; 59():469580221086142. PubMed ID: 35584986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public Health Crises In Comparison: China's Epidemic Response Policies From SARS To COVID-19.
    Li M
    Glob Public Health; 2021; 16(8-9):1223-1236. PubMed ID: 33891518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Government Information Dissemination During Public Health Emergencies: An Analysis of China's Experiences.
    Zhang Y; Shan J; Ye Z
    Front Public Health; 2022; 10():748236. PubMed ID: 35392466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policy disparities in response to the first wave of COVID-19 between China and Germany.
    Zhang Y; Shi L; Chen H; Wang X; Sun G
    Int J Equity Health; 2021 Mar; 20(1):86. PubMed ID: 33766049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Persistence and Change in China's Healthcare Insurance Reform: Clues from Fiscal Subsidy Policies Made for Settling COVID-19 Patients' Medical Costs.
    Ma T; Guo B; Xu J
    Risk Manag Healthc Policy; 2022; 15():1129-1144. PubMed ID: 35637742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Turning rural villages into the home front for social stability-Examination of coronavirus disease 2019 control experiences in rural areas in China.
    Zhang X; Xiang C
    Int J Health Plann Manage; 2020 Sep; 35(5):1250-1256. PubMed ID: 32677128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coevolution of COVID-19 research and China's policies.
    Cheng X; Tang L; Zhou M; Wang G
    Health Res Policy Syst; 2021 Sep; 19(1):121. PubMed ID: 34488797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.